BioSpace News Archive

CNTX-4975, Centrexion’s Phase 3 ready lead therapy, is a synthetic, ultra-pure injection of trans-capsaicin designed to be injected directly into the painful joint to provide rapid and durable pain relief.

Novoheart announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a three-tiered drug screening system with enhanced capability, sensitivity and accuracy for detecting pharmacological effects on heart contractility that cannot be achieved with conventional models.

The Millar catheter provides an easier way to measure pressures in these patients due to its reduced size and signal accuracy.

The Company’s Board appointed Mayes on Friday, January 12, 2018.

Berkeley Lights announced today that Novartis is implementing BLI’s Beacon platform to help accelerate their antibody discovery workflow.

DNAnexus today announced that the Genome10K’s (G10K) Vertebrate Genomes Project (VGP) will utilize the DNAnexus Platform in assembling and analyzing genomes of all vertebrate species, including 8,000 priority endangered species.

Acasti today announced that Neptune’s representatives, Rick Schottenfeld and Katherine Crewe, have resigned from Acasti’s Board of Directors.

Tetra Bio-Pharma announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005.

As CSO, Dr. Phillips will lead all scientific development projects and genomic and precision medicine research for Sequence Bio.

The position is a new one, as CANbridge ramps up its leadership in anticipation of upcoming regulatory filings expected for several of its programs